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A better understanding of the negative impact of general anesthetics on gastrointestinal
motility requires thorough knowledge of their molecular targets. In this respect the
muscarinic cationic current (mICAT carried mainly via TRPC4 channels) that initiates
cholinergic excitation-contraction coupling in the gut is of special interest. Here we
aimed to characterize the effects of one of the most commonly used “dissociative
anesthetics”, ketamine, on mICAT. Patch-clamp and tensiometry techniques were used
to investigate the mechanisms of the inhibitory effects of ketamine on mICAT in single
mouse ileal myocytes, as well as on intestinal motility. Ketamine (100 µM) strongly inhibited
both carbachol- and GTPγS-induced mICAT. The inhibition was slow (time constant of
about 1 min) and practically irreversible. It was associated with altered voltage dependence
and kinetics of mICAT. In functional tests, ketamine suppressed both spontaneous and
carbachol-induced contractions of small intestine. Importantly, inhibited by ketamine mICAT
could be restored by direct TRPC4 agonist (-)-englerin A. We identiﬁed mICAT as a novel
target for ketamine. Signal transduction leading to TRPC4 channel opening is disrupted by
ketamine mainly downstream of muscarinic receptor activation, but does not involve
TRPC4 per se. Direct TRPC4 agonists may be used for the correction of gastrointestinal
disorders provoked by general anesthesia.
Keywords: ketamine, (-)-englerin A, gastrointestinal tract, G-proteins, postoperative ileus, transient receptor
potential canonical subfamily member 4 channel

Abbreviations: CCh, carbachol; EA, (-)-englerin A; GI, gastrointestinal; Gmax, maximal conductance; I-V, current-voltage;
mAChR, muscarinic acetylcholine receptor; mICAT, muscarinic receptor cation current; POI, postoperative ileus; SM, smooth
muscle; TRPC4 (or TRPC5, TRPC6), Transient Receptor Potential Canonical subfamily member 4 (or 5, 6); V1/2, potential of
half-maximal activation.
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GRAPHICAL ABSTRACT

INTRODUCTION

In this study, based on our previous extensive investigation of
one of such putative targets of ketamine, namely muscarinic
receptor (mAChR) cation channels in the gastrointestinal (GI)
tract, which initiate cholinergic-excitation contraction coupling
in the gut (Zholos and Bolton, 1997; Bolton et al., 1999; Zholos
et al., 2004; Tsvilovskyy et al., 2009), we aimed to test such
effects of the drug on the underlying depolarizing inward
current termed mICAT that is mainly carried by
TRPC4 receptor-operated cation channels (Tsvilovskyy et al.,
2009). In this previous study involving TRPC4 and/or
TRPC6 knock-out mice, the functional impact of mICAT on
carbachol (CCh)-induced depolarisation, neurogenic ileal
contractions and small intestinal transit was demonstrated
(Tsvilovskyy et al., 2009).
Our interest has been prompted by the still unresolved
problem of one of the GI motility disorders—postoperative
ileus (POI), which imposes a signiﬁcant economic burden on
the healthcare system (Iyer et al., 2009) and for which there is no
effective pharmacological treatment (Lubawski and Saclarides,
2008; Harnsberger et al., 2019).
Thus, the aim of the present study was to systematically assess the
effects of ketamine on mICAT in isolated mouse ileal myocytes. We
found that ketamine at clinically relevant concentrations strongly
suppressed this current. While inhibition of mAChRs is apparently
not involved, downstream signaling cascades, most likely at the level
of G-proteins and/or beyond, appear to be the main targets. Most
interestingly, application of TRPC4 direct agonist (-)-englerin (EA)
can fully overcome ketamine-induced inhibition of mICAT. These

Ketamine (IUPAC Name: 2-(2-Chlorophenyl)-2-(methylamino)cyclohexan-1-one), ﬁrst synthesized in 1962 and included on the
WHO Essential Medicines List since 1985, is commonly used as an
anaesthetic and analgesic drug both for human and veterinary
applications worldwide. Its anesthetic properties were ﬁrst
described in 1965 (Domino et al., 1965). Moreover, ketamine is
now also increasingly recognized by WHO for its anti-depressant
and anti-seizure beneﬁts. The anesthetic action of ketamine is
believed to mainly result from its ability to inhibit the NMDA
receptor for excitatory amino acids as was initially characterised in
mouse hippocampal neurons (MacDonald et al., 1987). Since then a
number of other molecular targets of ketamine have been identiﬁed,
including neuronal hyperpolarization-activated cyclic nucleotide
channels, δ- and µ-opioid receptors, cholinergic receptors, GABA,
AMPA and metabotropic glutamate receptors, the NO-cGMP
signaling system, voltage-gated Na+ and L-type Ca2+-channels,
and large-conductance BKCa channels (Sleigh et al., 2014; Zanos
et al., 2018).
Such multiple-targeting action of ketamine can enhance its
anaesthetic and analgesic properties but can also cause certain
undesirable side effects. In addition, in connection with the
existence of multiple molecular targets, other uses of ketamine
are also being proposed owning to its anti-inﬂammatory and antidepressant properties, as well as bronchodilatory effects (Duman
et al., 2012; Kurdi et al., 2014; Niesters et al., 2014; Iadarola et al.,
2015; Li and Vlisides, 2016).
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currents were ﬁltered at 1 kHz and digitized at 10 kHz. For the
illustration purposes they were decimated with factor of 10. Mean
patch current was calculated as current integral after baseline
current correction to bring any background current to zero.
Before current recordings cells were kept in PSS, while for
recordings of mICAT the bath solution was replaced with a Cs+containing solution (in mM): CsCl 120, glucose 12, HEPES 10, pH
7.4 (adjusted with CsOH). The pipette solution contained (in mM):
CsCl 80, MgATP 1, creatine 5, glucose 5, BAPTA 10, HEPES 10,
CaCl2 4.6, pH 7.4 (adjusted with CsOH). Such symmetrical Cs+containing solutions help to isolate and maximize mICAT while
avoiding its intracellular Ca2+-dependent modulation (Gordienko
and Zholos, 2004) as the intracellular free Ca2+ concentration
([Ca2+]i) was “clamped” at 100 nM by the BAPTA/Ca2+ buffer.
mICAT was activated either by 50 µM CCh or, to bypass M2/M3receptors, by an infusion of 200 μM GTPγS added to the pipette
solution. BPS-8 solution exchange system (ALA Scientiﬁc
Instruments, Inc., New York, NY, United States) was used for
solution application. Complete exchange of the external solution
was estimated to take about 1 s.

results have been communicated in an abstract form at the
Physiology-2019 main meeting (Dryn et al., 2019).

MATERIAL AND METHODS
Animals
Animal studies were carried out in accordance with the
recommendations of the EU directive 2010/63. They also
conﬁrm to the guidelines of the UK Animals (Scientiﬁc
Procedures) Act 1986 and are reported in compliance with the
ARRIVE guidelines.
All experiments were performed on BALb/c two month-old
(25–30 g) wild type male mice housed under normal
environmental conditions at 21°C, 12 h light-dark cycle, with
free access to water and standard rodent chow. The mice were
humanely euthanized by cervical dislocation. The total number of
mice used was approximately 40.

Cells Isolation
The ileum longitudinal smooth muscle (SM) layer was rapidly
removed by carefully peeling the SM in the longitudinal direction
and placed into a normal physiological salt solution (PSS)
containing (in mM): NaCl 120, glucose 12, HEPES 10, KCl 6,
CaCl2 2.5, MgCl2 1.2, pH 7.4 (adjusted with NaOH). SM cells
were isolated by enzymatic digestion using (in mg/ml) 1
collagenase type 1A, 1 soybean trypsin inhibitor II-S, 1.5
bovine serum albumin in divalent cation-free PSS following
tissue incubated for 18 min at 36.5°C, as described in more
detail elsewhere (Dryn et al., 2018).

Intact Tissue Isometric Force Measurement
The entire thickness ileum segments (2 cm long) of the distal section
of the small intestine were dissected, mounted in a 2-ml organ bath
and continuously superfused using a peristaltic pump with a modiﬁed
Krebs-bicarbonate buffer solution (in mM): NaCl 133, KCl 4.7,
NaHCO3 16.3, NaH2PO4 1.38, CaCl2 2.5, MgCl2 1.2, HEPES 10,
D-glucose 7.8, pH adjusted to 7.4 with NaOH. Temperature was
maintained at 37°C. After a 40 min equilibration period at the resting
tension of 0.5 g the tissue isometric contractions were recorded by an
external force displacement transducer (AE 801, SensoNor A/S,
Norten, Norway) connected to an AD converter Lab-Trax 4/16
(World Precision Instruments, Inc., Sarasota, FL, United States).
The data were acquired at 10 kHz sampling frequency using
DataTrax2 software (World Precision Instruments, Inc., Sarasota,
FL, United States).

Electrophysiological Studies
Membrane currents were recorded in the whole-cell
conﬁguration of the patch-clamp techniques at room
temperature (22–25°C) using an Axopatch 200B voltage-clamp
ampliﬁer (Molecular Devices, San Jose, CA, United States).
Voltage-clamp pulses were generated and data were captured
using a Digidata 1322A interfaced to a computer running the
pClamp 8 program (Molecular Devices, San Jose, CA,
United States). Patch pipettes, made from borosilicate glass
(1.5 mm OD, 0.86 mm ID, Sutter Instrument Corp., Novato,
CA, United States) using a P-97 Flaming/Brown micropipette
puller (Sutter Instrument Corp., Novato, CA, United States), had
a resistance of 2.5–4 MΩ when ﬁlled with an intracellular
solution.
Whole-cell data were ﬁltered at 2 kHz and sampled at 10 kHz
for analysis. Series resistance was compensated for by ∼40%.
Holding potential was −40 mV. The steady-state current-voltage
relationships of mICAT were measured by applying either 1.2 s
duration voltage steps to test potentials ranging from −120 to
80 mV with a 10 mV increment at 5 s interval or by slow voltage
ramps from 80 to −120 mV lasting 6 s, which were applied every
30 s.
Single-channel activity was recorded in the outside-out
conﬁguration of the patch-clamp techniques. Membrane
patches were formed by slowly withdrawing the pipette from
the cell after whole-cell mICAT was induced by 50 µM CCh. These
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Materials
All reagents were obtained from Sigma Chemical (St. Louis, MO,
United States), except the ketamine purchased from Farmak
Joint-Stock Co. (Kyiv, Ukraine).

Measurements and Statistical Analysis
Different experimental protocols (e.g. treatments with CCh,
GTPγS or EA) were performed on the same day to reduce
the number of animals. No technical replicates (e.g. using
identical protocols) were made, groups for comparisons were
of equal size and no outliers were excluded from data analysis.
SM preparations and cells were randomly assigned to various
tests and data analysis was performed independently in a semiblinded manner whenever possible (it should be noted that the
inhibitory effects of ketamine were fairly obvious to the operator
even without data analysis). Group size was determined based
on our previous extensive experience studying mICAT, and in
particular on our recent similar study of mICAT inhibition
produced by isoﬂurane (Dryn et al., 2018). Current
amplitudes were normalized by cell capacitance to account
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FIGURE 1 | Kinetics and voltage dependence of carbachol-induced mICAT in mouse ileal myocytes. (A) Typical recording showing that 3 min after break-through
(to allow complete equilibration of the cytosol with the pipette solution containing 125 mM Cs+ that abolished any K+ currents) carbachol applied at sub-maximal
concentration of 50 µM induced a large inward current at the holding potential of −50 mV. (B) Current kinetics and voltage dependence were assessed in the same cell
shortly before carbachol application (top, control traces) and after mICAT reached peak amplitude (middle traces) using two different protocols shown in bottom
panels, either by applying slow (6 s) voltage ramp from 80 to −120 mV (bottom left panel) or a series of 1.2 duration voltage steps applied from a holding potential of
−40 mV to different test potentials ranging from −120 to 80 mV with a 10 mV increment at 5 s intervals (bottom right panel). (C) in the presence of the muscarinic agonist,
outside-out patch excision from the same cell revealed activity of multiple cation channels (C—closed state level, O1-O7—multiple openings as shown by dashed lines)
of 60 pS single-channel conductance that mainly mediate mICAT (Dresviannikov et al., 2006; Tsvilovskyy et al., 2009). (D) I–V relationships of mICAT measured in the same
cell with voltage ramp, at the end of each voltage step with voltage steps, as well as mean patch currents recorded at different test potentials, as indicated. (E) Mean I–V
curves measured in Ca2+, Mg2+-free, Cs+ containing external solution 3 min after break-through in control and at the peak response to 50 µM carbachol (n  8 in each
case). Grey bands show S.E.M. values. In each cell, current amplitude was normalized by cell capacitance to calculate current density expressed in pA/pF. Mean cell
capacitance was 33.9 ± 2.2 pF (n  8).

for variations in cell size. In experiments with ketamine,
responses before and after drug application were compared
in the same cell by calculating their ratio. This approach
using matched controls would allow power of 0.89 (if n  5)
and power of 0.96 (if n  6) to be achieved at α  0.05 (the
probability of rejecting the null hypothesis when it is true), if, for
example, current density was reduced from −14.1 pA/pF to
−7.9 pA/pF and standard deviation of the differences for
paired samples was 3.2, as was the case for ketamine
(100 µM) inhibition of GTPγS-induced current.
Data were analyzed and plotted using Clampﬁt 8 (Molecular
Devices, Sunnyvale, CA, United States) and OriginPro 2020b (v.
9.7.5.184) software (OriginLab Corporation, Northampton, MA,
United States). Descriptive data are given as mean (standard error
of the mean) with n indicating the number of preparations/cells
used for a particular set of measurements. For statistical
comparisons we used two-sided Student’s t-test (for two
groups) or in case of the relatively small sample sizes nonparametric tests that do not require the assumption of normal
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distribution of experimental values as detailed on the OriginLab
Homepage describing non-parametric statistics (OriginLab,
2020). In this case, two groups were compared using the
Mann–Whitney test for independent samples or the Wilcoxon
signed rank test for paired samples. Multiple groups were
compared using Friedman ANOVA. Conﬁdence intervals
where appropriate (e.g. for quotient of two means) were
calculated using GraphPad online tool (GraphPad QuickCalcs,
2020). Differences were considered signiﬁcant at p < 0.05.

RESULTS
Effects of Ketamine on Muscarinic Cation
Current Evoked by Carbachol or
Intracellular GTPγS
Experimental conditions used in this study allow efﬁcient
isolation of mICAT since all K+ currents are abolished using
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FIGURE 2 | Biophysical properties of intracellular GTPγS-induced mICAT in mouse ileal myocytes. (A) Voltage protocol and superimposed current traces recorded
in a mouse ileal myocyte at 30 s interval following break through with a patch pipette containing 200 µM GTPγS. (B) Time course of current amplitudes measured at
−40 mV (holding potential), −120 mV, and 80 mV, as indicated. (C) Superimposed mICAT I–V curves measured by slow voltage ramps. (D) Top panel, time constant of
GTPγS-induced mICAT deactivation during voltage step from -40 to -120 mV; middle and bottom panels, best-ﬁt parameters of the Boltzmann equation ﬁt of the
cation conductance curves: the maximal conductance (Gmax) and potential of its half-maximal activation (V1/2), respectively.

symmetrical Cs+ based solutions, while voltage-dependent Ca2+
current is abolished in Ca2+-free external solution. In addition, as
already mentioned, any Ca2+-dependent modulation of mICAT is
prevented by “clamping” intracellular free Ca2+ concentration at
100 nM using 10 mM BAPTA/4.6 mM Ca2+ mixture. As we showed
previously, under these conditions currents, in response to either
external carbachol or intracellular GTPγS application, show similar
biophysical properties, such as double rectiﬁcation around the
reversal potential and U-shaped I-V curve at negative potentials,
which are hallmarks of TRPC4-mediated currents (Zholos and
Bolton, 1994; Zholos and Bolton, 1996; Zholos and Bolton, 1997;
Zholos et al., 2004; Zholos et al., 2004). Moreover, this current is
inhibited by M2-and M3-selective muscarinic receptor antagonists
(Zholos and Bolton, 1997), intracellular GDPβS, pertussis toxin
treatment and anti-Gαi3/Gαo antibodies (Pucovsky et al., 1998;
Yan et al., 2003). Moreover, mICAT is strongly suppressed in
TRPC4−/− mice and it is completely abolished in TRPC4−/−/
TRPC6−/− mice (Tsvilovskyy et al., 2009).
Two different approaches for the activation of TRPC4
channels mediating mICAT have been used to identify the
molecular targets involved in ketamine-dependent inhibition
of the current. These channels are known to be activated in
synergy by M2 and M3 mAChRs, which are differentially coupled

Frontiers in Pharmacology | www.frontiersin.org

to Gi/o and Gq/11 proteins, respectively (Zholos and Bolton, 1997).
To differentiate between mAChR/G-protein gated and solely
G-protein activated mICAT we employed two different
strategies for mICAT activation. Following the ﬁrst one, mICAT
was activated by CCh (at sub-maximal concentration of 50 μM)
that initiated signal transduction at the mAChR level. Following
the second one, infusion of GTPγS (200 μM) into isolated mouse
ileal myocytes via a patch-pipette was used. In the latter case,
mAChRs are completely bypassed as GTPγS directly activates all
available trimeric G-proteins slowly and irreversibly.
Figure 1 illustrates measurements of carbachol-induced
currents. Speciﬁcally, Figure 1A shows typical example of the
time course of mIcat activation by 50 µM carbachol, while I-V
curves measured in the same cell using voltage steps or voltage
ramp protocols before and after carbachol application are shown
in Figure 1B. In the same cell, activity of the major 60 pS channel
mediating this current (Dresviannikov et al., 2006; Tsvilovskyy
et al., 2009) was recorded in an outside-out patch excised from the
same cell (Figure 1C). This channel was rigorously identiﬁed as
TRPC4 in TRPC4−/− mice (Tsvilovskyy et al., 2009). TRPC4
mediates >80% of the whole-cell mIcat as was found in that study.
The I–V curves for the whole-cell currents obtained with two
different voltage protocols together with the I–V curve for the
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FIGURE 3 | Ketamine strongly inhibits CCh-induced mICAT. (A) Time course of mICAT evoked by CCh (50 μM) and inhibited by ketamine (100 μM) application at
three different test potentials, as indicated. (B) Representative steady-state I–V relationships of mICAT at maximum response to CCh and during maximal current inhibition
by ketamine (i.e. at time points a and b indicated in panel A). (C) mICAT voltage-dependent deactivation kinetics during voltage step from −40 to −120 mV ﬁtted by single
exponential function (superimposed smooth black lines) at the same time points marked a and b in panel A. (D) Cation conductance activation curves were ﬁtted by
the Boltzmann equation shown by the superimposed smooth black lines. (E) Ketamine not only markedly reduced the maximal conductance (Gmax) (top panel), but also
shifted the potential of half-maximal activation (V1/2) positively (bottom panel). (F) Mean deactivation time constant of mICAT (top) and Gmax (bottom) in control and at
steady-state inhibition by ketamine.

mean patch current are shown in Figure 1D, as well as I–V curves
measured in control, that is 3 min after break-through and just
before carbachol application, and I–V curves of currents induced
in the same cells (n  8) after carbachol application (Figure 1E).
Having rigorously established appropriate experimental
conditions for carbachol-induced mICAT isolation and analysis
we further examined intracellular GTPγS-induced currents in
mouse ileal myocytes and found that these were highly similar to
CCh-induced currents with regard to their overall voltage
dependence (e.g. double rectiﬁcation around 0 mV, U-shaped
curve at negative potentials) and voltage-dependent relaxations
kinetics. Thus, Figure 2A illustrates superimposed current traces
recorded at 30 s interval following break through with of GTPγS
(200 μM) added to the pipette solution using the same voltage
ramp protocol as in Figure 1B. This maneuver produced a slowly
rising mICAT that reached its maximal amplitude typically during
5–7 min from the onset of cell perfusion as shown in Figure 2B.
The slow time course of current activation allowed us to
repeatedly evaluate biophysical properties (voltage dependence,
kinetics) of GTPγS-induced mICAT by applying voltage steps to
three different test potentials −40 (also holding potential), −120
and 80 mV, as well as slow voltage ramps from 80 to −120 mV at
30 s interval (Figure 2A, top panel). The wide range of test
potentials was required for the assessment of voltage

Frontiers in Pharmacology | www.frontiersin.org

dependence of mICAT and its possible alteration by ketamine,
while current amplitude at the holding potential of −40 mV,
which is close to the normal resting potential of these cells, was
the most relevant functionally. Accordingly, Figure 2B illustrates
typical time course of current development at the three test
potentials (e.g. mean current amplitudes during the last
100 ms segment at each test potential plotted vs. time), while
Figure 2C shows superimposed current-voltage (I–V)
relationships measured in the whole range of potentials by the
slow voltage ramp. These were doubly-rectifying around the
reversal potential (EREV was close to 0 mV in symmetrical
Cs+-containing solutions used) and U-shaped at negative
potentials, which is typical for mICAT (Figure 2C).
The rate of current deactivation during voltage steps from
−40 to −120 mV is an indication of mean channel open dwell
time at −40 mV (Figure 2D, top panel). mICAT deactivation
kinetics were clearly altered along with the accumulation of
G-proteins activated by GTPγS in the cell, as shown in
Figure 2D, top panel. From the steady-state I–V
relationships cation conductance activation curves were
constructed
(by
dividing
current
amplitude
by
electrochemical driving force at each potential), that could be
ﬁtted by a Boltzmann-type equation (see Figure 3D for an
example of such analysis). Best-ﬁt parameters, namely maximal

6
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FIGURE 4 | Comparison of ketamine action on mICAT evoked by CCh or GTPγS. (A, B) Time courses of average normalized 50 μM CCh-induced mICAT (a, n  8)
and 200 μM GTPγS-activated mICAT (b, n  6) in control (closed circles), during ketamine (100 μM) application (open circles) and after its wash-out. Superimposed
smooth lines show single exponential ﬁt of the data points with the time constant values indicated (Mann–Whitney Test: p < 0.05 for both). (C) Quantiﬁcation of the degree
and kinetics of mICAT inhibition by ketamine showing similar effects of ketamine on both CCh- (circles) and GTPγS- (squares) induced currents. 95% CI is shown by
the grey area for CCh- and by vertical lines for GTPγS-activated mICAT.

FIGURE 5 | EA-induced TRPC4 current is insensitive to ketamine. (A) Time course of TRPC4 current evoked by EA (10 nM) at three different test potentials, as
indicated, showing the lack of the inhibitory action of ketamine applied at 100 μM. (B) Mean steady-state I–V relationships of EA-induced current (10 nM) in control
(squares, n  5) and in the presence of ketamine (100 μM) (circles, n  5). (C) EA applied at 10 nM recovers mICAT activated by the application of CCh (50 µM) and then
suppressed by ketamine (100 µM). (D) Mean steady-state I–V relationships of CCh-induced current (50 μM) in control, in the presence of ketamine (100 μM) and
after application of EA, as indicated (n  5).

conductance (Gmax) and the potential of half-maximal
activation (V1/2) are plotted in Figure 2D, middle and
bottom panels, respectively. These reference data obtained in
control cells show 1) prolongation of mean open dwell time and
2) some negative shift of the activation curve of muscarinic
cation conductance along with gradual activation of G-proteins
by GTPγS. The data are representative of 14 measurements in

Frontiers in Pharmacology | www.frontiersin.org

different cells summarised elsewhere (Dryn et al., 2016). We
illustrate these phenomena here in control in order to contrast
them later with similar measurements in the presence of
ketamine.
CCh is a stable analogue of acetylcholine, the primary
neurotransmitter of the parasympathetic nervous system,
which binds to mAChRs and enhances TRPC4 channel
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FIGURE 6 | Ketamine inhibits both CCh-induced and spontaneous mouse ileum contractions. (A, B) Representative traces illustrating isometric contractions of
ileum segments in response to CCh (50 μM) followed by ketamine application (100 μM) in the continuous presence of CCh (A, n  9), or, alternatively, CCh application
following pretreatment with ketamine (B, n  10). Ketamine inhibited tonic component of the CCh-induced contraction with time constant of 0.91 ± 0.09 min as shown by
the smooth white superimposed line in panel (A). (C) Ketamine (100 μM) also inhibited spontaneous rhythmic contractions of the ileum with time constant of 1.61
min; 1 min duration segments marked 1 (control) and (2) at the steady-state inhibition by ketamine are shown on an expanded time scale. (D) Summary of the inhibitory
effects of ketamine on tonic (T, n  9) and phasic (Ph, n  10) components of CCh-induced contractions of the ileum and on its spontaneous (Sp, n  7) contractions.

3.5 nS to 7.5 ± 1.4 nS, V1/2 shifted from −70.4 ± 7.2 mV to
−61.7 ± 7.4 mV, or by 8.7 ± 2.0 mV positively (control vs.
ketamine, n  6, Wilcoxon signed rank test for paired samples,
p < 0.05).
These changes in biophysical properties of mICAT are similar
in magnitude, but opposite in direction compared to those that
occur during gradual G-protein activation (compare to
Figure 2D). Taken together with the slow development of
current inhibition one can conclude that ketamine acts as a
modiﬁer of channel gating, rather than a direct blocker of
TRPC4 channel pore, and that reduced G-protein activity is
somehow involved.
Thus, we next attempted to delineate the relative involvement
of mAChRs vs. G-proteins by comparing the inhibitory effect of
ketamine for CCh- vs. GTPγS-induced currents. As already
mentioned, GTPγs interacts directly with G-proteins avoiding
mAChRs resulting in very little current desensitization while
desensitisation with CCh was rather substantial (compare current
time courses in control shown by closed symbols in Figures 4A,B
and also note that traces shown in Figure 3A illustrate one
example corresponding to the averaged data shown by the open
circles in Figure 4A). The normalized maximum CCh-induced
current (Imax) at −40 mV was −15.1 ± 3.3 pA/pF in control, while
at steady-state ketamine-induced inhibition its amplitude (Iinh)
was −5.5 ± 0.9 pA/pF (n  8; p  0.014) (Figure 4A). At the same

activity through G-protein mediated signaling pathways
including PLC activation (Zholos et al., 2004), depletion of
PIP2 and direct channel gating by the activated Gi/o
α-subunits (Yan et al., 2003; Jeon et al., 2008; Otsuguro et al.,
2008; Jeon et al., 2012; Kim et al., 2012; Dryn et al., 2016). CCh
was applied at its sub-maximal concentration of 50 μM (Zholos
and Bolton, 1997; Yan et al., 2003). CCh-induced current
amplitudes measured at −40, −120, 80 mV potentials were
markedly decreased in a time-dependent manner after
ketamine (100 μM) application. It should be noted that the
effect developed slowly and there was no or very little recovery
of the response after the ketamine wash-out (Figure 3A). CChactivated mICAT with a mean peak amplitude of −556.5 ±
92.9 pA at the holding potential of −40 mV was reduced to
−199.9 ± 22.6 pA (n  8; p  0.002) (see Figure 3B for an
example). In parallel, voltage-dependent relaxation kinetics
during voltage step from −40 to −120 mV was accelerated
indicating considerable shortening of the mean open dwell
time (Figure 3C, mean time constant was reduced from
72.3 ± 10.6 ms to 38.0 ± 4.1 ms, control vs. ketamine;
Wilcoxon signed rank test for paired samples, n  6, p <
0.05), while activation curve progressively shifted towards
less negative potentials (Figure 3D) along with declining
Gmax as best-ﬁt Boltzmann equation parameters plotted in
Figure 3E show. On average, Gmax was reduced from 17.0 ±
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36.0 ± 4.0% (n  10; p < 0.001) was evident in this case
(Figure 6D), whereas tonic component was not signiﬁcantly
affected (Figure 6B). These results generally concur with the
above described inhibition of mICAT by ketamine.
Inhibition of spontaneous SM contractions by ketamine was
also evident and thus after ketamine application basal contractile
activity decreased by 34.0 ± 7.4% (n  7; p  0.004) (e.g. Figures
6C,D). The inhibition developed with time constant of about 1.6 min
(superimposed dotted line in Figure 6C). Parameters of the
spontaneous oscillatory contractions shown in Figure 6C were
compared in control and at their steady-state inhibition by
ketamine: peak amplitude—2.96 ± 0.03 g vs. 1.70 ± 0.02 g;
duration expressed as full width at half maximum ((FWHM)—
976 ± 4 ms vs. 837 ± 5 ms; area under the curve (i.e. muscle work)—
3.05 ± 0.03 g × s vs. 1.50 ± 0.02 g × s (control vs. ketamine, 86 tension
oscillations were analysed in each case; Mann–Whitney test for
independent samples, p < 0.05). This comparison is summarised in
Figure 6D. In contrast, frequency of these spontaneous contractions
remained unaltered (Figure 6C, portions of the trace marked 1 & 2
showing these on an expanded time scale).

concentration of ketamine mICAT induced by intracellular GTPγS
was reduced from Imax −349.6 ± 19.9 pA in control to the steadystate current level of −197.1 ± 41.7 pA (n  6; p  0.008).
Corresponding current densities were −14.1 ± 1.2 pA/pF in
control and −7.9 ± 1.3 pA/pF after ketamine application (p 
0.006). Both the degree and kinetics of current inhibition by
ketamine were practically identical in both cases (Figure 4C).
Such kinetics of current inhibition is slow enough to exclude any
direct blockage of the channel pore by the drug.
Preliminary dose-response studies were performed within the
limits of ketamine cytotoxicity, which occurs at concentrations
higher than 1 mM (Baker et al., 2016). Ketamine showed dosedependent inhibition of CCh-induced mICAT: the degree of
current inhibition recorded at the holding potential of −40 mV
at 1 mM was by 75.7 ± 3.7%, at 100 μM – 62.4 ± 2.6%, at 10 μM –
55.7 ± 3.6%, and at 1 μM – 37.2 ± 10.3% (n  5–8 for each
concentration).
EA has recently been identiﬁed as a highly selective and potent
direct activator of TRPC4 channels (Akbulut et al., 2015; Minard
et al., 2018). It was used to further clarify the mechanism of ketamine
action. Thus, application of ketamine at the peak response to EA
(10 nM) did not cause any signiﬁcant reduction of TRPC4 current
amplitude in the whole range of membrane potentials tested
(Figures 5A,B). Thus, EA-induced current density at −40 mV
was −30.8 ± 4.6 pA/pF in control declining non-signiﬁcantly to
−26.9 ± 3.9 pA/pF after ketamine application (Figure 5B, n  5; p 
0.536). Moreover, Figure 5C shows that mICAT activated by CCh
(average amplitude of −585.2 ± 90.1 pA) and then inhibited by
ketamine (mean amplitude of −287.4 ± 46.6 pA, decrease by 53%,
n  5; p  0.019), could be efﬁciently restored by EA (10 nM)
application. In fact, EA in the presence of ketamine increased mICAT
signiﬁcantly by 180% to −1,352.6 ± 349.7 pA (n  5; p  0.017).
Current densities at −40 mV were −15.2 ± 2.6 pA/pF, −7.3 ± 1.4 pA/
pF and −37.4 ± 8.1 pA/pF, in control, in the presence of ketamine
and in the presence of ketamine and englerin A, respectively
(Figure 5D, n  5).

DISCUSSION
Ketamine is one of the most widely-used unique dissociative
anesthetics and an important component of balanced anesthesia. Of
major relevance to the present study are its side effects related to GI
motility. Patients with chronic ketamine abuse present with problems
caused by SM relaxation in the upper GI tract (Pappachan et al., 2014).
In medical literature clear cut, albeit isolated, cases can be found
describing e.g. a profound paralytic ileus developing in patients treated
with ketamine for severe bronchospasm (Amoroso and Best, 1989).
Another more recent study showed that when ketamine-predominant,
opioid minimizing perioperative pain control protocol was
used the median time to return of bowel function was 3 days,
as opposed to 6 days with an opioid-predominant analgesic
regimen (Jacobsohn et al., 2015). Randomized controlled
trials showed the incidence of ileus associated with
intravenous ketamine use for postoperative analgesia in
patients undergoing laparoscopic cholecystectomy (Ye
et al., 2017). Impairment of GI motility by ketamine has
also been shown in several animal models, e.g. in pigs and
horses in vivo (Schnoor et al., 2005; Elfenbein et al., 2011), but
not in dogs (Fass et al., 1995).
Here, we show for the ﬁrst time that 1) 100 μM ketamine
similarly inhibits both CCh- and GTPγS-induced mICAT
(Figure 4C) suggesting that mAChRs per se are not the major
targets of its action, at least under our experimental conditions;
and 2) a novel potent agonist of TRPC4 channels, EA at 10 nM
can fully recover CCh-induced mICAT inhibited by 100 μM
ketamine (Figure 5). Strong suppression of mICAT under
conditions when mAChR function is bypassed via direct
activation of trimeric G-proteins by GTPγS strongly implies
that the inhibition occurs at the level of G-proteins or related
downstream pathways, such as PLC. Indeed, the latter is critically
important for mICAT generation (Zholos et al., 2004). mICAT is
also a strongly [Ca2+]i-dependent current (Gordienko and

Effects of Ketamine on Spontaneous and
Carbachol-Induced Contractions of Small
Intestine
Further functional tests of the ketamine action were performed
using in vitro intact tissue isometric force measurements. Two
different protocols of CCh and ketamine applications were used
and ketamine invariably caused inhibition of SM contractile
activity in all muscle strips tested. In the ﬁrst series of these
experiments, the whole ileum segments were ﬁrst pre-contracted
with CCh (50 μM). When CCh-induced contractions reached a
plateau the ketamine (100 μM) was applied resulting in the
inhibition of the tonic component of SM contraction by
36.2 ± 8.1% (n  7; p < 0.001) (Figures 6A,D). The inhibition
developed with a time constant of 0.91 ± 0.09 min as shown by the
white superimposed line in Figure 6A, which was compatible
with its similarly slow effect on mICAT (Figures 4A,B). In the
second series of experiments, CCh was applied in control and
then after about 20 min pre-treatment with ketamine, as
illustrated in Figure 6B. Inhibition of phasic component by
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Zholos, 2004) and ketamine was shown to inhibit noradrenalineinduced Ca2+ release in mesenteric resistance arteries (Akata
et al., 2001), but in our experiments we can safely exclude
from consideration impairment of Ca2+-signalling pathways by
ketamine when measuring mICAT since [Ca2+]i was strongly
buffered at 100 nM using 10 mM BAPTA. Altered voltagedependence and kinetics of mICAT in the presence of ketamine
(compare Figures 2 and 3) provide additional lines of evidence
favoring inhibition of G-proteins. In this context, it should be
noted that ketamine has high lipid solubility as it is a lipophilic
base that can thus easily reach intracellularly located targets.
Overall, ketamine induced inhibition of mICAT is highly
reminiscent of the effects of isoﬂurane (Dryn et al., 2018). To our
knowledge, our experiments provide ﬁrst indication that G-proteins
can be inhibited by ketamine, but obviously much further work is
required to clarify the underlying mechanism. In other studies it was
shown that Gαq-subunit was the main target point of local
anesthetics’ action on M1 receptors (Hollmann et al., 2001) and
in case of M3 receptors there was combined involvement of an
intracellular charged site on Gαq and an extracellular uncharged site
on the mAChR (Hollmann et al., 2001). In any case, our functional
assessment clearly shows that both mICAT and tonic component of
carbachol-induced ileal contraction, in the maintenance of which
mICAT is supposed to play a major role (as the major depolarizing
current for the activation of L-type Ca2+ channels), are inhibited by
ketamine with very similar kinetics (compare Figures 4A,B and
Figure 6A).
The evidence that TRPC4 channels are not directly affected by
ketamine can be summarised as following: 1) current inhibition
developed rather slowly, with time constant of about 1 min
(Figure 3A and Figures 4A,B), 2) it was associated with altered
voltage-dependence and deactivation kinetics of mICAT indicating
that ketamine acted as a gating modiﬁer rather than a direct channel
pore blocker (Figure 3C–E), and 3) most importantly, EA-induced
TRPC4 current was insensitive to ketamine (Figure 5A,B). EA, a
sesquiterpene from the bark of Phyllanthus englerin, is a novel
selective and potent agonist of TRPC4 and TRPC5 channels. It
activates TRPC4 channels directly, not via G-proteins pathway, and
at the external site of the plasma membrane (Akbulut et al., 2015;
Minard et al., 2018).
Nanomollar EA fully recovered CCh-induced mICAT
suppressed by ketamine (Figure 5C). These ﬁndings not only
contribute to our better understanding of the limited usefulness of
anticholinesterases (drugs that reduce breakdown of the
physiological neurotransmitter acetylcholine) for the treatment
of POI (Lubawski and Saclarides, 2008), but also show that the
activity of the muscarinic cation channels initiating cholinergic
excitation-contraction coupling in the gut could be restored by
channel agonists that do not require activation of mAChRs and
G-proteins.
Our study has some limitations. First, quantiﬁcation of
concentration-response dependence proved to be technically
difﬁcult since the inhibitory effect of ketamine developed very
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slowly and it was practically irreversible requiring numerous
measurements on separate cells. Second, we cannot exclude some
effects of ketamine on TRPC6 channels, which make a minor
(≈15%) contribution to mICAT (Tsvilovskyy et al., 2009). Third,
inhibition of L-type Ca2+-channels and/or PLC by ketamine is likely
to be partly responsible for its effects on SM contractions in our
functional tests (Figure 6) as InsP3 production and Ca2+ inﬂux
secondary to mICAT-induced depolarisation are ultimately required
for the maintenance of these responses. Clearly, these additional
targets of ketamine need to be addressed in future studies.
In summary, we demonstrate for the ﬁrst time that ketamine
suppresses mICAT carried mainly by TRPC4 channels, an effect
that could contribute to the development of POI, while
simultaneously propose a novel treatment strategy involving
direct activators of these channels.
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